ATE465172T1 - Peptidträger für die verabreichung von arzneimitteln - Google Patents

Peptidträger für die verabreichung von arzneimitteln

Info

Publication number
ATE465172T1
ATE465172T1 AT05730247T AT05730247T ATE465172T1 AT E465172 T1 ATE465172 T1 AT E465172T1 AT 05730247 T AT05730247 T AT 05730247T AT 05730247 T AT05730247 T AT 05730247T AT E465172 T1 ATE465172 T1 AT E465172T1
Authority
AT
Austria
Prior art keywords
drug administration
peptide carrier
therapeutic agents
delivery
peptide
Prior art date
Application number
AT05730247T
Other languages
English (en)
Inventor
Chinnaswamy Tiruppathi
Asrar Malik
Original Assignee
Univ Illinois
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Illinois filed Critical Univ Illinois
Application granted granted Critical
Publication of ATE465172T1 publication Critical patent/ATE465172T1/de

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/66Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid the modifying agent being a pre-targeting system involving a peptide or protein for targeting specific cells
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B82NANOTECHNOLOGY
    • B82YSPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004Oxidoreductases (1.)
    • C12N9/0065Oxidoreductases (1.) acting on hydrogen peroxide as acceptor (1.11)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Engineering & Computer Science (AREA)
  • Nanotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Medical Informatics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
AT05730247T 2004-03-05 2005-03-03 Peptidträger für die verabreichung von arzneimitteln ATE465172T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US55037304P 2004-03-05 2004-03-05
US55953204P 2004-04-05 2004-04-05
PCT/US2005/007442 WO2005087801A1 (en) 2004-03-05 2005-03-03 Peptide carrier for drug delivery

Publications (1)

Publication Number Publication Date
ATE465172T1 true ATE465172T1 (de) 2010-05-15

Family

ID=34975528

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05730247T ATE465172T1 (de) 2004-03-05 2005-03-03 Peptidträger für die verabreichung von arzneimitteln

Country Status (5)

Country Link
US (1) US7429563B2 (de)
EP (1) EP1730174B1 (de)
AT (1) ATE465172T1 (de)
DE (1) DE602005020755D1 (de)
WO (1) WO2005087801A1 (de)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010054699A1 (en) * 2008-11-17 2010-05-20 Affibody Ab Conjugates of albumin binding domain
US8906231B2 (en) 2009-09-10 2014-12-09 Lonza Biologics Plc Method and system for polypeptide purification
WO2018222929A1 (en) * 2017-05-31 2018-12-06 Prism | Proteogenomics Research Institute For Systems Medicine Enhanced targeted delivery of therapeutic agents
WO2020178574A1 (en) * 2019-03-04 2020-09-10 Bicyclerd Limited Synthesis of bicycle toxin conjugates, and intermediates thereof

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4018884A (en) 1975-06-26 1977-04-19 Hoffmann-La Roche Inc. Fluorogenic materials and labeling techniques
US4897255A (en) 1985-01-14 1990-01-30 Neorx Corporation Metal radionuclide labeled proteins for diagnosis and therapy
US4744981A (en) 1985-10-17 1988-05-17 Neorx Corporation Trichothecene antibody conjugates
EP0329184A3 (de) 1988-02-19 1990-05-23 Neorx Corporation Antimere und antimere Konjugation
US4988496A (en) 1988-05-31 1991-01-29 Neorx Corporation Metal radionuclide chelating compounds for improved chelation kinetics
US5460961A (en) * 1988-06-14 1995-10-24 La Region Wallonne Human myeloperoxidase and its therapeutic application
US5846799A (en) 1988-06-14 1998-12-08 La Region Wallone Human myeloperoxidase and its therapeutic application
AU643427B2 (en) 1988-10-31 1993-11-18 Immunex Corporation Interleukin-4 receptors
WO1991018982A1 (en) 1990-06-05 1991-12-12 Immunex Corporation Type ii interleukin-1 receptors
AU666853B2 (en) 1991-04-05 1996-02-29 Genentech Inc. Platelet aggregation inhibitors having high specificity for GP IIbIIIa
US5981194A (en) 1992-07-10 1999-11-09 University Of British Columbia Use of p97 and iron binding proteins as diagnostic and therapeutic agents
US5708009A (en) 1993-12-21 1998-01-13 Eli Lilly And Company Methods of inhibiting myeloperoxidase activity
WO1998007848A1 (en) * 1996-08-21 1998-02-26 Teikoku Hormone Mfg. Co., Ltd. Recombinant mpo fragment and method for assaying mpo autoantibody reaction site by using the same
CA2277519A1 (en) 1997-01-10 1998-07-16 Massachusetts Institute Of Technology Treatments for neurotoxicity in alzheimer's disease by .beta.-amyloid peptides
JP2003525038A (ja) 2000-02-08 2003-08-26 ユニバーシティー オブ ブリティッシュ コロンビア 治療薬をスクリーニングするための組成物および方法
AU2001283740A1 (en) 2000-08-17 2002-02-25 University Of British Columbia Chemotherapeutic agents conjugated to p97 and their methods of use in treating neurological tumours

Also Published As

Publication number Publication date
EP1730174A1 (de) 2006-12-13
US20070077239A1 (en) 2007-04-05
EP1730174A4 (de) 2008-05-07
DE602005020755D1 (de) 2010-06-02
WO2005087801A1 (en) 2005-09-22
EP1730174B1 (de) 2010-04-21
US7429563B2 (en) 2008-09-30

Similar Documents

Publication Publication Date Title
CY1118007T1 (el) Μεθοδοι για την χορηγηση υπογλυκαιμικων μεσων
EA200700118A1 (ru) Амидосоединения и их применение в качестве лекарственных средств
MY169272A (en) Her2 antibody composition
EA200870599A1 (ru) Стабильные препараты лаквинимода
EA200802170A1 (ru) Лиофилизированная композиция терапевтического пептидного антитела
EA200870366A1 (ru) Короткая внутренне сегментированная интерферирующая рнк
BRPI0510428A (pt) composições tópicas de metadona e processos para utilização das mesmas
MX2009005622A (es) Dihidro-imidazoles sustituidos y su uso en el tratamiento de tumores.
TW200621804A (en) Ctla-4 antibody and aromatase inhibitor combination treatment for breast cancer
CY1113115T1 (el) Πεπτιδια - αναστολεις συντηξης του ηiv με βελτιωμενες βιολογικες ιδιοτητες
EA200401526A1 (ru) Новые соединения и их применение
WO2007085629A3 (en) Use of hyaluronic acid as a carrier molecule for?different classes of therapeutic active agents
CY1112185T1 (el) Σταθερο συμπλοκο δραστικων ουσιων απο αλατα των o-ακετυλοσαλικυλικων οξεων με βασικα αμινοξεα και γλυκινη
ATE506957T1 (de) Prophylaktisches/therapeutisches mittel für neurodegenerative erkrankungen
UA100127C2 (ru) Пептид cdh3 и лекарственное средство, содержащее его
CY1109537T1 (el) Πεπτιδια και παραγωγα πεπτιδιου, παρασκευη αυτων καθως επισης χρηση αυτων για την παρασκευη θεραπευτικως η/και προληπτικως δραστικης φαρμακευτικης συνθεσης
DE602004014145D1 (de) Von rasgap-abgeleitetes peptid zur gezielten tötung von krebszellen
ATE507827T1 (de) Behandlung pervasiver entwicklungsstörungen
YU68702A (sh) Novi lhrh-antagonisti, njihova proizvodnja i upotreba kao leka
EA200700976A1 (ru) Соединения в виде молекул-конъюгатов, обладающих повышенной активностью в отношении включения клеткой
ATE465172T1 (de) Peptidträger für die verabreichung von arzneimitteln
EA200700403A1 (ru) ТРИЦИКЛИЧЕСКИЕ δ-ОПИОИДНЫЕ МОДУЛЯТОРЫ
EA201690966A1 (ru) Новое соединение для лечения тяжелой гипогликемии
AU6011001A (en) Novel lhrh-antagonists, production and use thereof as medicament
BRPI0516922A (pt) composto de ribavirina, método para fazer um composto de ribavirina, método para usar um composto de ribavirina e composição farmacêutica

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties